Treatment of Critical, Severe and Non-Severe COVID-19 by Corticosteroids
Journal Title: Medical Journal of Clinical Trials & Case Studies - Year 2020, Vol 4, Issue 1
Abstract
Glucocorticoids or corticosteroids have main anti-inflammatory effects to inhibit a vast number of pro-inflammatory genes that involve encoding of cell adhesion molecules, chemokines, cytokines, inflammatory receptors and enzymes to restore homeostasis and address the inflammatory process. A previous systematic review and meta-analysis revealed that severe COVID-19 patients were more likely to require corticosteroids treatment (RR = 1.56, 95 % CI = 1.28-1.90, p < 0.001). The length of stay (LOS) was longer in the corticosteroid group (WMD = 6.31, 95 % CI = 5.26-7.37, p < 0.001, I2 = 1.8 %, p = 0.361 as well as the same results in the subgroup analysis of SARS-CoV-infected patients (WMD = 6.34, 95 % CI = 5.24-7.44, p < 0.001, I2 = 50.3 %, p = 0.156). X et al demonstrated that COVID-19 patients treated with corticosteroids were more likely to be associated with harm, whereas Russell et al. concluded that either inhaled or systemic corticosteroid was distinguished. The WHO recommends systemic corticosteroids rather than no systemic corticosteroids for the treatment of critical and severe COVID-19 patients (strong recommendation, based on moderate certainty evidence). Even the WHO’s strong recommendations, these recommendations should not be applied to patients in whom the intervention is contraindicated as determined by the treating clinician. These recommendations are applied to critical and severe COVID-19 patients regardless of hospitalization status. The WHO suggests not using corticosteroids in treating non-severe COVID-19 patients (conditional recommendation, based on low certainty evidence). In conclusion, urge caution before using corticosteroids for ARDS-associated COVID-19. Corticosteroids are not recommended for mild COVID-19 patients. Moderate corticosteroids can be used in critical and severe COVID-19 patients. Currently, there has been no enough clinical trials or observational studies to examine the use of ICS in COVID-19. A rigorous blinded randomized multicentric clinical trials are urgently needed to further conclusion verification for the harm or benefit of corticosteroid treatment with confidence.
Authors and Affiliations
Attapon C* and Ruangrong C
Keywords
Related Articles
- EP ID EP756026
- DOI 10.23880/mjccs-16000S1-005
- Views 3
- Downloads 0
Ultrasound Diagnosis in Assessment of Structures and Functional Disorders in Distal Gastric Cancer
Objective: To evaluate the diagnostic possibilities of transabdominal ultrasonography for evaluation of severity of structures and functional disorders in distal gastric cancer (DGC). Materials and Methods: An analysis...
Neutrophil CD177 Flow Cytometric Expression as a Potential Myeloid Marker
Introduction: A specific clonality marker, may enhance diagnosis of myeloid neoplasms, particularly in challenging cases. Neutrophil CD177, being exclusive to the granulocytic series, could represent a good potential mar...
Medical Information from Internet for Tunisian Cancer Patients: A Double-Edged Weapon?
Background: Most cancer patients and/or their families consult the websites of scientific or patients’ associations to find answers about diagnosis, treatment protocols and side effects, making internet nowadays the eas...
Usage of Mobile Phone Applications for Dietary Benefits: Perceptions among Dietetics Professionals and Clients in Saudi Arabia
Mobile applications offer a basis for improving diet-based health outcomes and the study sought to investigate the usage of dietary mobile applications as perceived among dietetics professionals and clients. Results ide...
Omphalocele with Hypoalbunemia and Testicular Torsion
An Omphalocele is a birth defect in which an infant’s intestine or other abdominal organs are outside of the body because of a hole in the belly button (navel) area. The intestines are covered only by a thin layer of ti...